Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells $317,579.13 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the firm’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $26.73, for a total value of $317,579.13. Following the transaction, the chief operating officer directly owned 377,802 shares in the company, valued at $10,098,647.46. This trade represents a 3.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Monday, November 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.47, for a total value of $302,609.07.
• On Wednesday, October 28th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.45, for a total value of $338,014.45.
• On Monday, October 26th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $26.04, for a total value of $309,381.24.
• On Friday, October 23rd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $24.98, for a total value of $296,787.38.
• On Monday, October 19th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.05, for a total value of $285,738.05.
• On Wednesday, October 21st, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.41, for a total value of $301,896.21.
• On Thursday, October 15th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.61, for a total value of $304,272.41.
• On Tuesday, October 13th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.50, for a total value of $302,965.50.
• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $25.66, for a total value of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $29.19, for a total value of $346,806.39.

Adaptive Biotechnologies Stock Performance

NASDAQ:ADPT opened at $26.83 on Friday. The firm has a market cap of $4.28 billion, a PE ratio of -59.62 and a beta of 2.18. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $30.74. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The business has a 50 day moving average price of $26.39 and a 200-day moving average price of $19.81.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.12. Adaptive Biotechnologies had a negative net margin of 23.67% and a negative return on equity of 23.47%. The firm had revenue of $83.90 million for the quarter, compared to analysts’ expectations of $71.57 million. During the same quarter last year, the business earned $0.06 earnings per share. The business’s revenue was down 10.7% on a year-over-year basis. Equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current year.

Institutional Trading of Adaptive Biotechnologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nykredit A S purchased a new stake in Adaptive Biotechnologies in the second quarter worth about $31,000. Allworth Financial LP bought a new stake in Adaptive Biotechnologies during the 2nd quarter valued at approximately $35,000. KBC Group NV purchased a new position in shares of Adaptive Biotechnologies during the 1st quarter worth approximately $45,000. Integrated Wealth Concepts LLC purchased a new position in shares of Adaptive Biotechnologies during the 2nd quarter worth approximately $46,000. Finally, Assetmark Inc. raised its position in shares of Adaptive Biotechnologies by 46.4% in the 1st quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after acquiring an additional 1,401 shares in the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Morgan Stanley raised their price target on shares of Adaptive Biotechnologies from $22.00 to $27.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. The Goldman Sachs Group started coverage on shares of Adaptive Biotechnologies in a research note on Tuesday, September 29th. They set a “buy” rating and a $35.00 price objective for the company. National Bank Financial set a $34.00 price objective on shares of Adaptive Biotechnologies in a research note on Tuesday, September 22nd. TD Cowen increased their target price on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Finally, Guggenheim raised their target price on Adaptive Biotechnologies from $25.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.06.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive reported Q3 earnings of $0.02 per share, versus the consensus estimate of a $0.10 loss, and revenue of $83.9 million, above the $71.6 million expected. Management also said the company reached total-company profitability ahead of expectations. Quarterly results
• Positive Sentiment: Core MRD revenue grew 44%, and Adaptive raised its 2026 MRD revenue outlook to $276 million–$286 million. The company also outlined a target average selling price of $1,700–$1,800, signaling confidence in continued growth of this business. MRD outlook
• Neutral Sentiment: COO Julie Rubinstein sold 11,881 shares under a pre-arranged Rule 10b5-1 plan and retained a substantial stake. The planned nature of the sales may make them less informative about her outlook, though insider selling can draw investor attention. Insider sale report
• Negative Sentiment: Despite the quarterly beat, revenue was down 10.7% from a year earlier, and the company continued to report a negative net margin. Investors may look for sustained growth and profitability beyond this quarter. Earnings results

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation (NASDAQ: ADPT) is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and research tools. Based in Seattle, Washington, the company analyzes immune-cell receptors to help identify and measure disease, support drug development and improve understanding of immune responses.

Adaptive’s products include clonoSEQ, a clinical assay used to detect and monitor measurable residual disease in certain blood cancers, including multiple myeloma, acute lymphoblastic leukemia and chronic lymphocytic leukemia.